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ABSTRACT
INTRODUCTION: Hepatocellular carcinoma (HCC) is а leading cause of cancer-related death globally. 
Our study aimed to provide an understanding of the risk factors, pattern and management of HCC in a re-
al-life practice.
MATERIALS AND METHODS: Two hundred and forty consecutive patients with HCC were evaluated 
for an 11-year period (from 2006 to 2016). During the last 5 years the patients were followed up prospective-
ly from the time of the diagnosis to their death.
RESULTS: A hundred and seventy-two males and 68 females (mean age 66.4±10.3 and 62.4±9.5 years, re-
spectively) were included in the observation. Hepatitis B virus (HBV) infection accounted for 40.4% and 
hepatitis C virus (HCV) infection – for 25.8% of the aetiology of liver disease. Cirrhosis is a baseline con-
dition in 82%. HCC was found to be a first complication of liver disease in 2/3 of the studied patients. Us-
ing Barcelona Clinic Liver Cancer staging system HCC can be categorised as: stage 0 (n=3); stage A (n=32); 
stage B (n=52); stage C (n=75) and stage D (n=103). Therefore, the prevalence of very early and early HCC was 
13%. Radical therapy (resection or ablation) was recommended in 28% of the patients. Importantly, 18 of 55 
(32.7%) patients after surgical resection were followed for more than 3 years without tumour relapse. The 
median survival, based on the main treatment was: 36 months after surgical resection; 24 months after ab-
lation; 10.5 months for patients on Sorafenib; 9.5 months after TACE and only 3 months for palliative care.
CONCLUSION: Our study confirms the observed trends in underlying diseases, the heterogeneity of sur-
vival and underscores the need of early diagnosis of HCC.
Keywords: hepatocellular carcinoma, hepatitis B, hepatitis C, surveillance, survival
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tomography (CT) or magnetic resonance imaging 
(MRI)] with established typical intensive arterial hy-
perenhancement followed by slow and late washout 
and/or US or CT-guided liver biopsy. The stage was 
defined according to BCLC staging and allocation 
system (3). Treatment decision was taken by multi-
disciplinary discussion conducted by a local Oncolo-
gy Board. The liver resection and local ablation were 
considered to be potentially curative or radical treat-
ment methods. The main modalities for monitoring 
were US, including CEUS, level of alpha-fetoprotein 
and contrast-enhanced CT. The survival was calcu-
lated from the date of diagnosis. All patients’ data 
were registered in the Access-based data system. 
RESULTS
Two hundred and forty consecutive patients 
(172 males, 68 females) were registered with hepa-
tocellular carcinoma in Clinic of Gastroenterolo-
gy in Varna for the period from 2006 to July 2017 
(for 11.5 years). The mean number of 20 newly di-
agnosed cases were included per year, without any 
significant trend in the distribution. The male to fe-
male ratio was 2.6:1. The youngest patient with HCC 
was 36 years old. The average age at diagnosis of male 
and female patients was 66.40±10.31 and 62.44±9.55 
years, respectively. The main reason for diagnostic 
evaluation was nonspecific complaints (53.56%), fol-
lowed by decompensation of cirrhosis (30.12%) and 
lesion found on surveillance via conventional ultra-
sound (16.32%). During the last 5 years the part of 
occasionally diagnosed HCCs during monitoring 
with US has increased to 22.72%. 
Overall, cirrhosis is a baseline disease in most 
of our patients: 196 out of 240 (82%). Decompensat-
ed liver disease at the time of HCC presentation was 
found in 136 out of 196 patients (69.4%).
Risk Factors for HCC and Aetiology of Chron-
ic Liver Disease
Chronic HBV infection was registered in 40.4% 
of patients with HCC, chronic HCV infection – in 
25.8%; 2 cases had HBV/HCV co-infection and 4 
cases had HBV/HDV co-infection. Only 2 out of 97 
patients with hepatitis B had positive HBeAg (2%), 
thus predominant HBeAg negativity was observed. 
The viral load in patients with HBV infection was 
notably high: 6 585 589 IU/mL. Most of patients with 
HBV-related HCC, 74 out of 97 (76.3%) had never 
INTRODUCTION
Hepatocellular carcinoma (HCC) accounts for 
more than 80% of the primary liver malignancy. The 
main risk factors are well described: the chronic hep-
atitis B (HBV) and C (HCV) viral infections; severe 
and continuous alcohol consumption and fatty liv-
er disease, related to insulin resistance. Cirrhosis is 
a premalignant condition in 80 to 90% of established 
HCCs (1,2). In our country there is no approved al-
gorithm for surveillance of high-risk patients for de-
velopment of HCC in order to improve early diagno-
sis. However, a well-organised programme for eval-
uation and treatment of chronic viral infections has 
been adopted in clinical practice, leading to excellent 
achievements using the antiviral therapy. The diag-
nostic approach in patients with suspected HCC usu-
ally combines the utility of both imaging and biopsy 
methods as the morphological confirmation of diag-
nosis is essential for the patients before starting sys-
temic therapy, based on the National Oncology Al-
gorithm. Decisions on management were taken after 
discussion conducted by the local Oncology Board. 
The treatment of HCC is dependent on the Barcelo-
na Clinic Liver Cancer (BCLC) and TNM staging of 
the disease, as well as regional resources.
MATERIALS AND METHODS
This study involved patient data from a single 
referral centre in the St. Marina University Hospital 
and is a first report of the results of a project enti-
tled Hepatocellular Carcinoma – a Current Diagnos-
tic and Therapeutic Approach. We aimed to increase 
the percentage of patients with chronic advanced liv-
er disease included in surveillance for HCC with reg-
ular ultrasound (US) exams at every 6 months. The 
other important goals were to assess the risk factors 
for established HCC, to characterise the baseline 
chronic liver disease and the diagnostic and thera-
peutic methods for HCC in clinical practice. Patients 
diagnosed with HCC in an 11-year period (from 2006 
to 2016) were included in the study. During the last 
five years the patients were followed up prospectively 
from the time of the diagnosis to their death. US ex-
ams, including contrast enhanced US with SonoVue 
contrast agent (Bracco) were performed with Aloca 
α7 Prosound machine. HCC was diagnosed based on 
at least one imaging contrast-enhanced investigation 
[contrast-enhanced ultrasound (CEUS), computed 
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received antiviral treatment. Further, primary liv-
er cancer was diagnosed in 19 patients on long-term 
(over 1 year) nucleoside (Lamivudine, Telbivudine, 
Entecavir)/nucleotide (Tenofovir) analogue therapy 
against HBV or were previously treated with inter-
feron-alpha. Interestingly, 6 out of 18 (33%) patients 
on continuous antiviral therapy were registered with 
resistance to Lamivudine and additionally 4 patients 
failed to achieve complete viral suppression, defined 
as undetectable HBV DNA during treatment with 
Entecavir or Tenofovir. The patients with HCV in-
fection were previously untreated (87%) or were non-
responders to interferon-alpha therapy. One patient 
in our registry was followed up from the onset of the 
acute phase of HBV infection; he was treated with 
3 cycles of interferon (IFN)-alpha, achieving HB-
sAg seroconversion; HCC developed after 20 years of 
HBV infection in an HBsAg-negative phase (proba-
ble occult HBV infection). 
The prevalence of antibodies to HBV core anti-
gen (anti-HBc total or IgG), as a marker for previous 
HBV exposure, in the subgroup of patients with neg-
ative screening for HBV and HCV (HBsAg negative, 
anti-HCV negative) was significant - 56.52%.
The prevalence of diabetes was 35%. Moderate 
to severe alcohol intake was registered in 23% of pa-
tients. The other rare aetiologic factors for chronic 
liver disease in our cohort were: Wilson’s disease in 3 
cases; autoimmune hepatitis in 2 cases and non-alco-
holic fatty liver disease (NAFLD) in 1 patient (Fig. 1). 
Unknown aetiology was registered in 28 patients, but 
10 of them (36%) had a marker for exposure to HBV 
(anti HBc positive antibodies). 
Abbreviations used in Fig. 1: HBV (hepatitis B 
virus); HCV (hepatitis C virus); WD (Wilson’s dis-
ease); AIH (autoimmune hepatitis); NAFLD (non-al-
coholic fatty liver disease); UNK (unknown).
Characteristics and Severity of Underlying 
Liver Disease
HCC was associated with cirrhosis in 196 pa-
tients (82% of the studied cohort). A hundred and 
forty-six cases (75%) can be defined with clinically 
significant portal hypertension, based on the pres-
ence of oesophageal varices (n=91) or ascites (n=121), 
or both (n=67) at time of HCC diagnosis. HCC was 
found to be a first complication of chronic liver dis-
ease in 2/3 of cases (n=156). The prevalence of oe-
sophageal varices was 63%. Table 2 summarised the 
clinical and laboratory characteristics of chronic liv-
er disease in the involved 240 patients.
Remarkable trends in laboratory results in the 
studied cohort of 240 patients can be synthesised as: 
mild but present liver synthetic function dysfunc-
tion; platelet count higher than expected for the se-
verity of liver disease; predominant cholestasis than 
cytolysis; disturbed glucose metabolism (fasting glu-
cose ≥6 mmol/L) in 44% of the cases. However, the 
conclusion could not be proved due to absence of 
comparison to other similar cohort of patient with 
cirrhosis without malignant transformation.
Twenty-one HCC patients had a liver stiffness 
measurement, with mean value of 27.85 kPa (ranged 
from 4.4 to 75 kPa, with the lowest value in a patient 
on a long-term antiviral therapy with Tenofovir and 
the highest value in a patient with severe portal hy-
pertension, respectively). 
Test
Number of positive patients/ 




Anti-HBc total (or IgG) 111/128 (86.72)
Anti-HDV 4/80 (5)
Table 1. Viral markers in patients with hepatocellular 
carcinoma 
Fig. 1. Risk factors and aetiology of chronic liver disease 
in the cohort of patients with hepatocellular carcinoma 
(n=240)
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Methods for Diagnosis of HCC
The primary diagnosis of HCC was based on at 
least two imaging methods in 133 cases (55.4%); in 
all other patients the imaging method was combined 
with at least one US or CT-guided biopsy of the he-
patic lesions (Fig. 2). The fine needle aspiration biop-
sy (FNAB) was a morphologic method in 92 patients 
(86% of all performed biopsies) and the core biopsy 
for histology – in 15 patients. The false negative rate 
of biopsy investigation for malignancy in our cohort 
was 14%. 
Overall, contrast-enhanced US and CT were 
the principal imaging modalities in our practice. Re-
garding the staging of HCC we have got a small ex-
perience with PET/CT imaging in 7 patients. Data on 
diagnostic accuracy of used modalities will be pre-
sented in a future report.
Abbreviations used in Fig. 2: US (ultrasound); 
CEUS (contrast-enhanced ultrasound); CT (comput-
ed tomography); MRI (magnetic resonance imag-
ing); FNAB (fine needle aspiration biopsy).
We analysed the level of tumour markers in the 
studied cohort. Overall, 77.5% of the patients diag-
nosed with HCC had elevation of alpha-fetoprotein 
(AFP); 95 patients with HCC (40%) had AFP serum 
concentration greater than 200 ng/mL and 85 pa-
tients (35.4%) - above 360 ng/mL. Interestingly, 70% 
of patients with elevated AFP had also increased car-
bohydrate antigen 19-9 (CA 19-9).  
Tumour Burden and Staging
A solitary lesion (with mean diameter 5.2 cm) 
was registered in one third of the studied patients. A 
total of 50% of the patients had more than 3 lesions 
at the time of the diagnosis of the disease or were 
presented with poorly defined infiltrative pattern of 
malignancy (Fig. 3). A hundred and thirty-one cas-
es (54.5%) had bilobar distribution of nodules. Sixty-
Characteristics Results
Child-Turcotte-Pugh class of the chronic liver disease: A/B/C; n (%) 90 (37.5%) / 73 (30.4%) / 77 (32.1%)
Performance status: 0/1/2/3/4 (n) 29 / 117 / 52 / 36 / 3
Oesophageal varices: small/large, n 29 / 62
Portal hypertensive gastropathy, n (%) 99 (68.3%)
Ascites: mild/ moderate/ severe (n) 45 / 35 / 46
Bilirubin, mcg/L (mean ± SD) 55.4 ± 77.6
Prothrombin index, % (mean ± SD) 68 ± 23.2
Albumin, g/L (mean ± SD) 32.2 ± 7.3
Haemoglobin, g/L (mean ± SD) 122.9 ± 20.1
Platelet count, x109 /l 172.8 ± 34.8
AST, IU/L (mean ± SD) 113.1 ± 121.8
ALT, IU/L (mean ± SD) 67.2 ± 70.4
GGT, IU/L (mean ± SD) 241.6 ± 288.5
AP, IU/L (mean ± SD) 327.7 ± 414.7
Cholinesterase activity, IU/l (mean ± SD) 3887.3 ± 3047
Glucose, mmol/L (mean ± SD) 6.4 ± 2.7
Table 2. Clinical and laboratory data of 240 studied patients with hepatocellular carcinoma
Fig. 2. Methods for diagnosis of HCC
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two cases had major vessel invasion (26%), predomi-
nantly malignant thrombosis of the portal vein and/
or its main branches. Thirty-nine patients (16.2%) 
were diagnosed with regional lymph node enlarge-
ment and another 32 cases (13.2%) had distant me-
tastasis in lungs, bones, suprarenal glands, pleura, 
abdominal wall and central nervous system. 
Using the accepted Barcelona Clinic Liver Can-
cer (BCLC) staging system the disease can be catego-
rised as: stage 0 (n=3); stage A (n=32); stage B (n=52); 
stage C (n=75) and stage D (n=103), Figure 4. The pa-
tients with very early and early HCC stage account-
ed for 13% of all HCCs; the tumour had been detect-
ed with ultrasound surveillance in 51%. In contrast, 
most HCCs were detected at stage D, mainly due to 
advance baseline liver cirrhosis.
Regarding the CLIP, scoring the patients can 
be assessed in seven categories: with score 0 (n=12); 
score 1 (n=41); score 2 (n=54); score 3 (n=34); score 4 
(n=46); score 5 (n=25) and score 6 (n=10).
Treatment Methods
Overall, radical therapy (resection or ablation 
of HCC) was recommended in 28% of studied pa-
tients (Fig. 5). Surgical resection (anatomical/seg-
mental or atypical resection) was performed in 23% 
of the cases (n=55). The perioperative mortality rate 
and short-term lethal evolution due to severe liver 
decompensation were registered in 7.3% of the treat-
ed patients by radical surgical intervention. Impor-
tantly, 18 out of 55 (32.7%) patients with radical re-
section were followed up for more than 3 years (me-
dian 4.2 years) without relapse of HCC. In all oth-
er cases a relapse of HCC was registered during the 
first 3 to 24 months after surgery, treated by further 
resection (n=3), local ablation (n=4), systemic thera-
py with Sorafenib (n=8) or palliation (n=15). Medi-
an survival of patients treated by surgical resection 
was 36 months. In 13 patients (5%) the first treat-
ment method was the local ablation, mainly radio-
frequency ablation. Complete ablation, confirmed by 
follow-up CEUS was achieved in 61% and there were 
no serious complications leading to death. The me-
dian survival of patients treated by local ablation was 
24 months. No patient with HCC was treated by liv-
er transplantation. 
To summarise, radical treatment of HCC in 
our cohort was successful to achieve disease-free and 
overall survival in 26 patients; the carcinoma was 
established by US follow-up in 70%; all these cases 
had viral aetiology of chronic liver disease (in stage 
of compensated cirrhosis at a prevalence of 77%) and 
radical treatment of HCC was accompanied by con-
tinuous viral suppression in HBV-related carcino-
mas. Modern treatment with direct-acting antiviral 
agents (Sofosbuvir/Ledipasvir ± Ribavirin) was in-
troduced to 4 patients with HCV cirrhosis and re-
sults on HCV eradication and HCC follow-up will be 
further evaluated. 
We have small experience with TAE/TACE 
(mainly TAE) as a first-line therapy in 2% of studied 
patients with median survival of 9.5 months. System-
ic therapy, predominantly with Sorafenib was intro-
duced to 17% of involved patients and median sur-
vival was registered as 10.5 months. Most frequent 
method, however, was best supportive care (in 53%), 
including treatment of liver cirrhosis decompensa-
tion. Overall survival of these patients was 3 months. 
Fig. 3. Pattern of tumour lesions
Fig. 4. Classification of HCC, according to the Barcelona 
Clinic Liver Cancer staging system (n=240)
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In addition, antiviral treatment during and after 
treatment for HCC was recommended in 28 patients 
with viral cirrhosis. 
Finally, we tried to analyse the efficacy of in-
terventions as a part of prospective surveillance and 
management of patients after 2012 and after inclu-
sion in a project for HCC best care. Table 3 sum-
marises the observed difference in tumour burden 
and stage of HCC and recommendation for poten-
tial curative treatment, according to application of 
US surveillance. 
DISCUSSION
Epidemiology of HCC is changing globally and 
trends show an increasing morbidity in North, Cen-
tral and Eastern Europe and North America but a 
slow decline in Japan, Korea and China. The bur-
den of this important complication of the chronic 
advanced liver disease is expected to increase in the 
next 10 years (4). Several reviews were focused on a 
broad spectrum of clinical practice in HCC manage-
ment worldwide, including surveillance of patients 
with cirrhosis for HCC, establishing the diagnosis of 
HCC, and various therapeutic options for the treat-
ment of HCC (5-11). Thus, we initiated a project to 
gather a real-life data from a large tertiary referral 
centre for patients with chronic liver disease in Bul-
garia, including multidisciplinary team of specialists, 
involved in HCC management.
Our observation registered 240 patients with 
HCC for a 11-year period without significant in-
crease of new cases in the last 5 years. Two impor-
tant manuscripts on HCC management in Bulgaria 
were published recently (12,13). The study from St. 
Ivan Rilski University Hospital involved 65 consecu-
tive HCC patients for an approximately 3-year inter-
val (12). The report from Queen Giovanna Universi-
ty Hospital was focused on 450 patients with prima-
ry liver neoplasms for an 11-year period (1997-May 
2017) (13). 
It is well known, that male to female predomi-
nance is greater than 2:1 with HCC, and a 2.6:1 ra-
tio is recorded in our cohort. Cirrhosis is a baseline 
disease in 80 to 90% of the cases in clinical series, as 
82% registered in this study. Interestingly, the largest 
observation on HCC in Bulgaria showed even high-
er percentage of HCCs – 99.1%, based on liver cir-
rhosis (13). 
The most common risk factor for HCC was 
HCV in North America, Europe and Japan, and HBV 
in China, South Korea and Taiwan (5). In contrast to 
data from Europe, in Bulgaria the principal aetiolo-
gy for liver disease complicated with HCC was HBV. 
HBV infection accounted for 40.4% and HCV infec-
tion – for 25.8% of aetiology of liver disease in our 
observation. We may further speculate on the even 
more significant role of HBV (as occult or infection 
in the past) if we consider the high prevalence of pos-
itive HB core antibodies (56%) in persons with neg-
ative screening for active HBV and HCV infection. 
A vaccination programme in newborns against HBV 
infection in Bulgaria started in 1992 and its favour-
able impact on HBV-related HCCs is expected prob-
ably in the near future. Table 3 summarised gener-
al features of HCC, according to published literature. 
The conclusion is that in our region we need 
to focus on early diagnosis of HCC, simultaneously 
with registration of HCC in patients with compen-
Fig. 5. First-line treatment method in a cohort of 240 
patients with hepatocellular carcinoma
Fig. 6. Overall survival of 240 patients with hepatocellular 
carcinoma, according to the BCLC stage of disease
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sated liver disease, mainly cirrhosis. This favourable 
“stage migration” can be achieved with surveillance 
with US and tumour markers like AFP among pa-
tients with advance liver disease, particularly with 
HBV aetiology. Although the early stage of HCC is 
much lower (13%) than recorded in European and 
US registries we were able to recommend and per-
form curative treatment in 28% of patients. That ap-
plicability rate is in accordance with 25-40% use of 
curative therapy in Western series and leads to fa-
vourable survival rate. 
Finally, the ultrasound monitoring of patients 
with advanced chronic liver disease registered an in-
creased rate of BCLC 0-1 staged tumours (46%) and 
the applicability of potentially curable treatment ap-
proach, achieving best survival rate of median 42.5 
months. Thus, our pilot study provided evidences, 
promoting systematic use of surveillance in the pa-
tients at risk of having HCC.
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